Monitoring the KMT2A gene post‐chemotherapy independently predicts the relapse and survival risk after allogeneic haematopoietic stem cell transplantation - Liu, Jing; Zhao, Xiao‐Su; Chang, Ying‐Jun; Qin, Ya‐Zhen; Jiang, Qian; Jiang, Hao; Zhang, Xiao‐Hui; Xu, Lan‐Ping; Wang, Yu; Lv, Meng; Liu, Kai‐Yan; Huang, Xiao‐Jun; et al. (British journal of haematology, 2025)
Keywords: acute myeloid leukaemia; Acute myeloid leukemia; Adolescent; Adult; Aged; allogeneic haematopoietic stem cell transplantation; Allografts; Chemotherapy; Diagnosis; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic stem cells; Histone-Lysine N-Methyltransferase - genetics; Humans; KMT2A; Leukemia; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - mortality; Leukemia, Myeloid, Acute - therapy; Male; measurABLe residual disease; Medical prognosis; Middle Aged; MLL protein; multiparameter flow cytometry; Myeloid-Lymphoid Leukemia Protein - genetics; Prognosis; Recurrence; Risk factors; Stem cell transplantation; Transplantation, Homologous; Young Adult; measurABLe residual disease; multiparameter flow cytometry; KMT2A; acute myeloid leukaemia; allogeneic haematopoietic stem cell transplantation